NO329402B1 - Orale farmasoytiske sammensetninger med mesalazin-kontrollert frigivelse og fremgangsmate ved fremstillingen derav. - Google Patents

Orale farmasoytiske sammensetninger med mesalazin-kontrollert frigivelse og fremgangsmate ved fremstillingen derav. Download PDF

Info

Publication number
NO329402B1
NO329402B1 NO20016107A NO20016107A NO329402B1 NO 329402 B1 NO329402 B1 NO 329402B1 NO 20016107 A NO20016107 A NO 20016107A NO 20016107 A NO20016107 A NO 20016107A NO 329402 B1 NO329402 B1 NO 329402B1
Authority
NO
Norway
Prior art keywords
active ingredient
matrix
compositions according
lipophilic
hydrophilic
Prior art date
Application number
NO20016107A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016107D0 (no
NO20016107L (no
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329402(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of NO20016107D0 publication Critical patent/NO20016107D0/no
Publication of NO20016107L publication Critical patent/NO20016107L/no
Publication of NO329402B1 publication Critical patent/NO329402B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20016107A 1999-06-14 2001-12-14 Orale farmasoytiske sammensetninger med mesalazin-kontrollert frigivelse og fremgangsmate ved fremstillingen derav. NO329402B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001316A ITMI991316A1 (it) 1999-06-14 1999-06-14 Composizioni farmaceutiche orali a rilascio modificato di mesalazina
PCT/EP2000/005321 WO2000076481A1 (fr) 1999-06-14 2000-06-08 Compositions pharmaceutiques orales a liberation regulee a base de mesalazine

Publications (3)

Publication Number Publication Date
NO20016107D0 NO20016107D0 (no) 2001-12-14
NO20016107L NO20016107L (no) 2002-02-11
NO329402B1 true NO329402B1 (no) 2010-10-11

Family

ID=11383159

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016107A NO329402B1 (no) 1999-06-14 2001-12-14 Orale farmasoytiske sammensetninger med mesalazin-kontrollert frigivelse og fremgangsmate ved fremstillingen derav.

Country Status (18)

Country Link
US (1) US6773720B1 (fr)
EP (2) EP1287822B1 (fr)
JP (2) JP4727875B2 (fr)
CN (2) CN100448448C (fr)
AT (2) ATE324104T1 (fr)
AU (1) AU5077200A (fr)
CA (1) CA2377299C (fr)
DE (2) DE60001835T2 (fr)
DK (2) DK1287822T3 (fr)
ES (2) ES2262749T3 (fr)
HK (1) HK1046247B (fr)
IT (1) ITMI991316A1 (fr)
MX (1) MXPA01012888A (fr)
NO (1) NO329402B1 (fr)
PT (2) PT1198226E (fr)
RU (1) RU2245148C2 (fr)
TR (1) TR200200561T2 (fr)
WO (1) WO2000076481A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183014B1 (fr) 1999-06-14 2003-10-08 Cosmo S.p.A. Compositions pharmaceutiques administrables par voie orale a liberation controlee et gout masque
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2359812C (fr) * 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
CA2520197A1 (fr) * 2003-04-23 2004-11-04 Ferring B.V. Sachet pour composition pharmaceutique
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
WO2005072113A2 (fr) 2004-01-20 2005-08-11 Harty Richard F Compositions et procedes pour traiter des maladies inflammatoires
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
AU2007275660B2 (en) * 2006-07-19 2012-08-02 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
WO2008033125A1 (fr) * 2006-09-13 2008-03-20 The Procter & Gamble Company Procédés de traitement d'une rectocolite hémorragique utilisant de l'aminosalicylate
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
US20100035850A1 (en) 2006-11-17 2010-02-11 Shire Development Inc. Method of treatment for inflammatory bowel disease
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011045775A1 (fr) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited Composition pharmaceutique à libération retardée de mésalamine
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2425826A1 (fr) * 2010-09-01 2012-03-07 Disphar International B.V. Comprimé de mésalazine doté d'une dissolution améliorée
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
EP2468264A1 (fr) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Comprimé pharmaceutique oral pour la libération prolongée de mésalazine et son procédé de fabrication
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EA033067B1 (ru) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2013144176A1 (fr) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Formulation à libération contrôlée comprenant de la mésalamine
WO2013158928A2 (fr) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Thérapies à base de ligand de récepteur chimiosensoriels
CA2878625A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
EP2722058A1 (fr) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Composition orale solide contenant des colorants convenant pour diagnostic endoscopique
CN105101956B (zh) 2013-01-05 2018-12-07 埃尔舍利克斯治疗公司 包含双胍的延迟释放组合物
AU2014219726B2 (en) * 2013-02-22 2018-03-15 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
JP6294457B2 (ja) 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN104922090B (zh) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 美沙拉秦肠溶缓释微丸
EP3162362A1 (fr) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Comprimé optimisé a une haute dose contenant de la mesalazine
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
EP3544638A1 (fr) 2016-11-28 2019-10-02 Cosmo Technologies Ltd. Composition orale solide contenant des colorants
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (fr) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Composition pour administration solide
EP3662895A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Procédé de fabrication de noyaux de comprimés réduisant le 5-asa sans sucre
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CN112587506A (zh) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 一种用于制备美沙拉嗪肠溶缓释胶囊的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (ja) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
JPH0624962A (ja) * 1992-07-09 1994-02-01 Green Cross Corp:The 腸溶徐放性製剤
DE69332291T2 (de) * 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
WO1998026767A2 (fr) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Formulations a liberation lente et specifique d'un site, pour l'administration de mesalazine
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
EP1183014B1 (fr) * 1999-06-14 2003-10-08 Cosmo S.p.A. Compositions pharmaceutiques administrables par voie orale a liberation controlee et gout masque

Also Published As

Publication number Publication date
EP1198226B1 (fr) 2003-03-26
ES2262749T3 (es) 2006-12-01
DK1198226T3 (da) 2003-07-21
DE60027608D1 (de) 2006-06-01
CN1355694A (zh) 2002-06-26
JP4727875B2 (ja) 2011-07-20
DK1287822T3 (da) 2006-08-28
JP2010024241A (ja) 2010-02-04
RU2245148C2 (ru) 2005-01-27
EP1287822A3 (fr) 2003-03-19
EP1287822A2 (fr) 2003-03-05
NO20016107D0 (no) 2001-12-14
CN100448448C (zh) 2009-01-07
EP1287822B1 (fr) 2006-04-26
CA2377299A1 (fr) 2000-12-21
PT1287822E (pt) 2006-07-31
DE60001835D1 (de) 2003-04-30
HK1046247A1 (en) 2003-01-03
WO2000076481A1 (fr) 2000-12-21
DE60027608T2 (de) 2007-04-26
MXPA01012888A (es) 2002-07-30
US6773720B1 (en) 2004-08-10
ES2194732T3 (es) 2003-12-01
ITMI991316A0 (it) 1999-06-14
JP5235839B2 (ja) 2013-07-10
CA2377299C (fr) 2009-05-12
CN1720919A (zh) 2006-01-18
CN1217665C (zh) 2005-09-07
HK1085669A1 (zh) 2006-09-01
PT1198226E (pt) 2003-07-31
JP2003501458A (ja) 2003-01-14
EP1198226A1 (fr) 2002-04-24
ATE324104T1 (de) 2006-05-15
HK1046247B (zh) 2006-04-07
AU5077200A (en) 2001-01-02
TR200200561T2 (tr) 2002-06-21
NO20016107L (no) 2002-02-11
ATE235234T1 (de) 2003-04-15
DE60001835T2 (de) 2003-11-13
ITMI991316A1 (it) 2000-12-14

Similar Documents

Publication Publication Date Title
NO329402B1 (no) Orale farmasoytiske sammensetninger med mesalazin-kontrollert frigivelse og fremgangsmate ved fremstillingen derav.
US8293273B2 (en) Controlled release and taste masking oral pharmaceutical composition
DK200300005U3 (da) Farmaceutiske pellets indeholdende tamsulosin
WO2007136151A1 (fr) Comprimés matriciels à libération prolongée de metformine
Limmatvapirat et al. Modulation of drug release kinetics of shellac-based matrix tablets by in-situ polymerization through annealing process
NO20121414A1 (no) Farmasoytiske sammensetninger omfattende hydromorfon og nalokson
JPH0587488B2 (fr)
EP3179987A1 (fr) Composition pharmaceutique d'etoricoxib
GB2420708A (en) Tetracycline controlled release pharmaceutical composition
Raffick et al. Preparation and evaluationof in-vitro release kinetics of novel bilayer metoprolol succinate as sustained release and amlodipine besylate as immediat release tablets
HK1085669B (en) Mesalazine controlled release oral pharmaceutical compositions

Legal Events

Date Code Title Description
MK1K Patent expired